FIRM REPORT

Samsung Biologics report




A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

02-28-2017

Full financial report of Samsung Biologics

   KRW per share 
 Price  164,500.00
 Dividend  0.00
 Earnings  29,375.00
 Cash-flow  -4,012.20
 Book value  42,179.49
 Equity  0.00

Samsung Biologics is a company from Korea specialized in Pharmaceuticals and Biotechnology sector, which is part of Health Care industry. Samsung Biologics shares are publicly traded at Korea stock exchange.

On the date of this report, Samsung Biologics shares trade at 164,500.00 KRW after performing a 0.00% last year.

The equity of Samsung Biologics is composed by 66 million shares. The company has a free float of 21% from total capizatilation. Finally, Samsung Biologics capitalizacion (equity market value) is 10,857,000 million KRW.

Some of the main competitors of Samsung Biologics within the Pharmaceuticals and Biotechnology sector are: Cipla, Kalbe Farma, Shanghai Pharmaceuti, Mochida Pharm, TORRENT PHARMACEUTIC, Amgen Corp, China Traditional Ch, UCB Cap, Celltrion Inc, Taisho Pharmaceutica, Jazz Pharmaceuticals, China Medical System, ...

   PER   P/BV   P/CF   ROE   Div.Y   Payout 
Samsung Biologics 5.60 3.90 -41.00 0.00% 0.00% 0.00%
Global 17.22 3.10 12.63 14.11% 2.58% 40.24%
Korea 15.11 1.66 9.87 9.99% 1.67% 19.66%
Health Care 22.96 5.66 21.42 19.68% 1.45% 33.63%
Pharmaceuticals and Biotechnology 21.96 6.28 22.12 19.07% 1.54% 34.93%

Next, we analize Samsung Biologics financial situation on the basis of accounting information from Dec 15. We will compare several multipliers and ratios of Samsung Biologics with the average of the world, other companies from Korea, its industry "Health Care", and finally in its sector "Health Care". That way we can know if the company is over or undervalued.

Finally, last month performance of Samsung Biologics shows a 2.20% return compared to a 2.56% of the hole stock market. Over the last year, the company has performed a 0.00% versus a market return of a 2.20%.

The following graph compares the performance of Samsung Biologics with the return obtained by Korea, Health Care and Pharmaceuticals and Biotechnology companies, both for last month and last year. Here can be appreciated that Samsung Biologics has obtained a lower return than both the market and other firms of the Health Care industry, which have obtained a return of 21.63% and 10.71% respectevely.

Samsung Biologics compared stock return

Next companies

Samsung Card. Korea. Financials.
Samsung Electro-Mech. Korea. Industrials.
Samsung Electronics. Korea. Consumer Goods.
Samsung Eng. Korea. Industrials.
Samsung F & M Ins. Korea. Financials.
Samsung Fine Chem. Korea. Basic Materials.

Previous companies

Samsonite Internatio. Hong-Kong. Consumer Goods.
Sampo Oyi. Finland. Financials.
Salvatore Ferragamo. Italy. Consumer Goods.
Salesforce.com. USA. Technology.
Saipem. Italy. Oil and Gas.
Sainsbury (J). UK. Consumer Services.

All rights reserved

 information advertisement legal

Dividends Ranking | Firm Report | Price to BookValue | Price to Cash-Flow | Price to Earnings | Return on Equity

Part of Enciclopedia Financiera Group

Disclaimer: Information on this site is only for informational purposes. Always consult a professional advisor before investing.